ISO certification Company

Ask For A Quote Here

TransEnterix, Inc. vs. Medtronic

Robotic surgery upstart TransEnterix (NYSEMKT: TRXC) has taken a more severe beating than most. The stock rose sharply in anticipation of FDA clearance for its SurgiBot system, then crashed when the regulator deemed it "not substantially equivalent" to existing devices in April. Unfortunately, we can't predict ALF-X's potential based on sales achieved since earning European marketing approval (a CE mark) in 2011, because there haven't been any. TransEnterix has its hopes pinned to a robotic surgery system that hadn't made a sale after years on the European market.

Go To Top

Go To Top